Skip to main content

Advertisement

Table 1 Characteristics of subjects [mean ± SD or N (%)] during baseline and follow-up periodsa by status at follow-up (hypertensive, nonhypertensive)

From: Associations between serum uric acid and the incidence of hypertension: a Chinese senior dynamic cohort study

Characteristic Hypertensive subjects (N = 744) Nonhypertensive subjects (N = 2847) P-value hypertensive versus nonhypertensive
Baseline Follow-up Baseline Follow-up Baseline Follow-up
Male (%) 570 (76.61 %) 1980 (69.55 %) 0.000 0.000
Female (%) 174 (23.39 %) 867 (30.45 %)   
Age (years) 61.47 ± 11.66 63.82 ± 11.63 55.61 ± 13.41 56.64 ± 13.33 0.000 0.000
BMI (kg/m2) 24.85 ± 3.04 24.76 ± 2.92 24.06 ± 3.03 24.01 ± 3.00 0.000 0.000
Overweight (BMI = 24–27.9 kg/m2) 350 (47.0 %) 346 (46.5 %) 1115 (40.5 %) 1130 (39.7 %)
Obese (BMI ≥ 28 kg/m2) 105 (14.1 %) 96 (12.9 %) 268 (9.4 %) 253 (8.9 %)
TG (mg/dl) 148.85 ± 95.69 149.73 ± 82.40 131.13 ± 95.69 134.67 ± 93.05 0.000 0.000
TC (mg/dl) 188.27 ± 32.47 189.82 ± 30.54 186.34 ± 32.47 186.73 ± 30.54 0.165 0.023
HDL (mg/dl) 51.80 ± 15.46 51.03 ± 14.69 53.35 ± 15.46 53.35 ± 15.46 0.059 0.000
eGFR (ml/min/1.73 m2) 86.96 ± 17.03 86.62 ± 15.69 90.51 ± 18.15 91.31 ± 22.62 0.000 0.000
≥60 (ml/min/1.73 m2) 711 (95.6 %) 712 (95.7 %) 2727 (95.8 %) 2738 (96.2 %)
<60 (ml/min/1.73 m2) 33 (4.4 %) 32 (4.3 %) 120 (4.2 %) 109 (3.8 %)
SUA (mg/dl) 6.26 ± 1.38 5.65 ± 1.20 5.50 ± 1.33 5.47 ± 1.27 0.000 0.000
BUN (mg/dl) 15.41 ± 3.53 15.49 ± 2.97 14.54 ± 3.53 14.57 ± 3.36 0.000 0.000
SCR (mg/dl) 0.92 ± 0.21 0.91 ± 0.18 0.88 ± 0.18 0.88 ± 0.17 0.000 0.000
SBP (mmHg) 140 140 119.62 ± 10.97 119.60 ± 10.46 0.000 0.000
DBP (mmHg) 90 90 70.01 ± 8.83 69.59 ± 8.41 0.000 0.000
FBG (mg/dl) 92.44 ± 22.71 98.93 ± 21.26 92.08 ± 18.02 94.42 ± 16.58 0.682 0.000
TP (g/L) 75.28 ± 4.06 74.69 ± 3.51 82.38 ± 10.83 73.68 ± 3.68 0.000 0.000
GLB (g/L) 29.66 ± 3.36 29.56 ± 3.07 28.27 ± 3.42 28.15 ± 3.27 0.000 0.000
ALB (g/L) 45.62 ± 2.61 45.12 ± 2.14 45.67 ± 2.70 45.52 ± 2.51 0.641 0.000
ALT (IU/L) 28.63 ± 22.08 25.25 ± 12.29 23.26 ± 17.98 22.19 ± 11.90 0.000 0.000
TBIL (mg/dl) 0.82 ± 0.29 0.90 ± 0.29 0.82 ± 0.31 0.84 ± 0.29 0.265 0.000
DBIL mg/dl) 0.12 ± 0.07 0.17 ± 0.10 0.19 ± 0.11 0.20 ± 0.09 0.000 0.000
Hypertension incidence (2007–2011)
 2006 n/incidence (baseline/follow-up) 0/0.00 % (932/821)     
 2007 n/incidence (baseline/follow-up) 155/9.15 % (1694/1567)     
 2008 n/incidence (baseline/follow-up) 191/11.27 % (1695/1636)     
 2009 n/incidence (baseline/follow-up) 157/8.92 % (1761/1683)     
 2010 n/incidence (baseline/follow-up) 122/6.89 % (1770/1615)     
 2011 n/incidence (baseline/follow-up) 119/5.73 % (2077/2077)     
  1. BMI body mass index; TG plasma levels of triglycerides; TC total cholesterol; HDL high-density lipoprotein; eGFR estimated glomerular filtration rate; SUA serum uric acid; BUN blood urea nitrogen; SCR serum creatinine; SBP systolic blood pressure; DBP diastolic blood pressure; FBG fasting plasma glucose; TP plasma total protein; GLB globulin; ALB albumin; ALT alanine aminotransferase; TBIL total bilirubin; DBIL direct bilirubin
  2. aMeans during the follow-up period are specified observations starting from the time of the baseline visit through the last visit or incidence of hypertension